Rekombinanter EGFR (Zalutumumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter EGFR (Zalutumumab Biosimilar) Antikörper (ABIN7487875)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Zalutumumab Biosimilar - Anti-EGFR mAb
-
Produktmerkmale
- Antibody Type: IgG1-kappa
-
Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotyp
- IgG1 kappa
-
-
-
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Buffer
- PBS pH 7.5
-
Lagerung
- -80 °C
-
Informationen zur Lagerung
- store at -80°C
-
-
- EGFR (Zalutumumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
-
HuMax-EGFr
Zalutumumab (proposed trade name HuMax-EGFR) is a high affinity, completely human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR, also known as ErbB1/HER1). It is developed by Genmab and designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. Zalutumumab is derived from transgenic mice immunized with A431-derived EGFR. -
CAS-Nummer
- 667901-13-5
Target
-